logo
Plus   Neg
Share
Email

Skyepharma Reports Reorganisation Of Swiss Operations - Quick Facts

SkyePharma Plc (SKYEY.PK,SKP.L) announced that the SkyePharma Group has entered into a consultation process which could lead to a reduction of nearly 20% of its 101-strong workforce in Muttenz, Switzerland. The company noted that the proposed steps are planned to improve its competitiveness and generate CHF 2.6 million or 1.8 million pounds of operating cost savings each year.

Separately, the Group reached deals with the Aenova Group to sub-let part of its laboratory space in Muttenz and sell some of its surplus laboratory equipment to Aenova. Aenova intends to use the space to expand its own non-competing oral product development activities and has agreed to consider offering positions to some of the SkyePharma employees potentially affected by the headcount reduction.

The changes would not affect relationships with existing or potential customers and the Group would continue to provide its full existing range of innovative oral and inhalation drug delivery solutions.

In future, SkyePharma plans to make greater use of third-party sub-contracting for certain aspects of the oral product development process and Aenova has agreed to be a sub-contractor for this purpose. There would be no transfer or disposal of any business, technology or intellectual property to Aenova and Aenova's oral product development activities do not directly compete with those of SkyePharma.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
BJ's Wholesale Club Holdings Inc., which is planning a return to the public market, has set terms for its planned initial public offering or IPO. In a filing with the U.S. Securities and Exchange Commission, the warehouse club operator said Monday that it plans to offer 37.5 million shares priced between $15 and $17 per share. At the top end of the range, the offering would raise $637.5 million. Shares of Valeant Pharmaceuticals International Inc. are falling more than 6 percent in Monday's trading following news that the U.S. Food and Drug Administration has failed to approve the Canada-based company's Duobrii lotion for the treatment of plaque psoriasis. Ortho Dermatologics, a division of Valeant Pharmaceuticals, said it has received a Complete Response Letter or CRL from the FDA. Reigniting concerns about a global trade war, President Donald Trump announced plans to impose new tariffs on billions of dollars worth of Chinese imports on Friday. Trump said in a statement the U.S. will implement a 25 percent tariff on $50 billion of goods from China that contain "industrially significant technologies."
Follow RTT